Association of ACE2 and TMPRSS2 genes variants with disease severity and most important biomarkers in COVID-19 patients in Bosnia and Herzegovina
- PMID: 38868968
- PMCID: PMC11157263
- DOI: 10.3325/cmj.2024.65.220
Association of ACE2 and TMPRSS2 genes variants with disease severity and most important biomarkers in COVID-19 patients in Bosnia and Herzegovina
Abstract
Aim: To assess the association of single nucleotide polymorphisms (SNPs) in the ACE2 and TMPRSS2 genes with COVID-19 severity and key biomarkers.
Methods: The study involved 750 COVID-19 patients from Bosnia and Herzegovina, divided into three groups: mild, moderate, and severe cases. Genetic variations within the ACE2 (rs2285666) and TMPRSS2 (rs2070788) genes were examined with real-time polymerase chain reaction. Biochemical markers were determined with standard procedures.
Results: There was a significant difference in the rs2070788 genotype distribution between patients with mild and moderate symptoms, but not between other groups. For the rs2285666 polymorphism, no significant difference in genotype distribution was found. In patients with mild symptoms, carriers of the GG genotype of rs2070788 had significantly higher total bilirubin levels than carriers of the AA genotype. Similarly, carriers of the TT genotype of rs2285666 had significantly higher activated partial thromboplastin time and international normalized ratio, and lower lactate dehydrogenase levels compared with the CC genotype. Among patients with severe symptoms, carriers of the GG genotype showed significantly higher potassium levels than carriers of the AA genotype, while carriers of the TT genotype showed significantly higher erythrocyte count as well as hemoglobin and hematocrit levels compared with the CC genotype.
Conclusion: This study highlights the role of genetic factors, particularly SNPs in the ACE2 and TMPRSS2 genes, in determining COVID-19 severity, aiding patient risk assessment and prognosis.
Similar articles
-
Genetic Association between ACE2 (rs2285666 and rs2074192) and TMPRSS2 (rs12329760 and rs2070788) Polymorphisms with Post-COVID Symptoms in Previously Hospitalized COVID-19 Survivors.Genes (Basel). 2022 Oct 24;13(11):1935. doi: 10.3390/genes13111935. Genes (Basel). 2022. PMID: 36360172 Free PMC article.
-
Role of ACE2 and TMPRSS2 polymorphisms on COVID-19 outcome and disease severity in adult patients: A prospective cohort study in a tertiary hospital, Indonesia.Narra J. 2024 Aug;4(2):e919. doi: 10.52225/narra.v4i2.919. Epub 2024 Aug 12. Narra J. 2024. PMID: 39280326 Free PMC article.
-
Mutations in ace2 gene modulate cytokine levels and alter immune responses in Mycobacterium tuberculosis and SARS-CoV-2 co-infection: a Cameroonian cohort.Front Immunol. 2025 Mar 24;16:1533213. doi: 10.3389/fimmu.2025.1533213. eCollection 2025. Front Immunol. 2025. PMID: 40196114 Free PMC article.
-
Polymorphisms and mutations of ACE2 and TMPRSS2 genes are associated with COVID-19: a systematic review.Eur J Med Res. 2022 Feb 22;27(1):26. doi: 10.1186/s40001-022-00647-6. Eur J Med Res. 2022. PMID: 35193695 Free PMC article.
-
Single Nucleotide Variants (SNVs) of Angiotensin-Converting Enzymes (ACE1 and ACE2): A Plausible Explanation for the Global Variation in COVID-19 Prevalence.J Renin Angiotensin Aldosterone Syst. 2023 Apr 3;2023:9668008. doi: 10.1155/2023/9668008. eCollection 2023. J Renin Angiotensin Aldosterone Syst. 2023. PMID: 37051471 Free PMC article. Review.
Cited by
-
Role of Artificial Intelligence in Identifying Vital Biomarkers with Greater Precision in Emergency Departments During Emerging Pandemics.Int J Mol Sci. 2025 Jan 16;26(2):722. doi: 10.3390/ijms26020722. Int J Mol Sci. 2025. PMID: 39859435 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases